Abstract:AIM:To evaluate the bioequivalence of ranitidine and bismuth derived from two compound preparations.METHODS:The bioavailability was measured in 20 healthy male Chinese volunteers following a single oral dose (equivalent to 200 mg of ranitidine and 220 mg of bismuth) of the test or reference products in the fasting state. Then blood samples were collected for 24 h. Plasma concentrations of ranitidine and bismuth were analyzed by high-performance liquid chromatography and inductively coupled plasma-mass spectrometry (ICP-MS), respectively. The non-compartmental method was used for pharmacokinetic analysis. Log-transformed C(max), AUC( (0-t) ) and AUC( (0-infinity) ) were tested for bioequivalence using ANOVA and Schuirmann two-one sided t-test. T(max) was analyzed by Wilcoxon's test.RESULTS:Various pharmacokinetic parameters of ranitidine derived from the two compound preparations, including C(max), AUC( (0-t)), AUC( (0-infinity)), T(max) and T((1/2)), were nearly consistent with previous observations. These parameters derived from test and reference drug were as follows: C(max) (0.67 +/- 0.21 vs 0.68 +/-0.22 mg/L), AUC( (0-t) ) (3.1 +/- 0.6 vs 3.0 +/- 0.7 mg/L per hour), AUC( (0-infinity) ) (3.3 +/- 0.6 vs 3.2 +/- 0.8 mg/L per hour), T(max) (2.3 +/- 0.9 vs 2.1 +/- 0.9 h) and T((1/2)) (2.8 +/- 0.3 vs 3.1 +/- 0.4 h). In addition, double-peak absorption profiles of ranitidine were found in some Chinese volunteers. For bismuth, those parameters derived from test and reference drug were as follows: C(max) (11.80 +/- 7.36 vs 11.40 +/- 6.55 microg/L), AUC( (0-t) ) (46.65 +/- 16.97 vs 47.03 +/- 21.49 microg/L per hour), T(max) (0.50 +/- 0.20 vs 0.50 +/- 0.20 h) and T((1/2)) (10.2 +/- 2.3 vs 13.0 +/- 6.9 h). Ninety percent of confidence intervals for the test/reference ratio of C(max), AUC( (0-t) ) and AUC( (0-infinity) ) derived from both ranitidine and bismuth were found within the bioequivalence acceptable range of 80%-125%. No significant difference was found in T(max) derived from both ranitidine and bismuth.CONCLUSION:The two compound preparations are bioequivalent and may be prescribed interchangeably.

Research and Bioequivalence of Ibuprofen Liquid Suspension

Pharmacokinetic and bioequivalence studies of ibuprofen suspension after a single-dose administration in healthy Chinese volunteers.

Relative Bioavailability of (s) - ( + ) -Ibuprofen Suspension in Human Subjects

Study on bioequivalence of cilostazol table in healthy volunteers

Bioequivalence of Ibuprofen,pseudoephedrine and Chlorphenamine for Tablet and Suspension in Healthy Volunteers

Relative bioequivalence of fusidic acid suspension in healthy volunteers

Relative bioavailability and bioequivalence of ibuprofen orally disintegrating tablets in healthy volunteers

Bioavailability of Cefuroxime Axetii Suspension in Healthy Volunteers

Clinical Pharmacokinetics of Cefprozil and Bioequivalence Between Its Tablet and Suspension

The Bioequivalence of Cefpodoxime Oral Suspension in Healthy Volunteers

Relative Bioavailability of Ibuprofen Sustained-release Capsules in Human Subjects

Bioequivalence of Amoxycillin-Clavulanic Acid Tablet and Suspension

Study on Bioequivalence of Risperidone Tablets

Pharmacokinetics and Bioequivalence of Ranitidine and Bismuth Derived from Two Compound Preparations

Physiologically Based Pharmacokinetic Model Development and Verification for Bioequivalence Testing of Bempedoic Acid Oral Suspension and Reference Tablet Formulation

Bioequivalence Study of High Performance Liquid Chromatography Towards Cefetamet Pivoxil

Study on Bioequivalence of Glucosamine Indometacin Enteric-coated Tablets in Healthy Volunteers

The Pharmacokinetics and Bioequivalence of Diflunisal Dispersible Tablets in Healthy Volunteers

Pharmacokinetics and Bioequivalence Study of Cefixime Tablet in Healthy Volunteers

A Study of the Bioequivalence of Fleroxacin Tablets in Healthy Chinese Volunteers

Bioequivalent assessment of imported arginine and ibuprofen granules